Does BEVACIZUMAB Cause Second primary malignancy? 89 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 89 reports of Second primary malignancy have been filed in association with BEVACIZUMAB (JOBEVNE). This represents 0.1% of all adverse event reports for BEVACIZUMAB.
89
Reports of Second primary malignancy with BEVACIZUMAB
0.1%
of all BEVACIZUMAB reports
29
Deaths
21
Hospitalizations
How Dangerous Is Second primary malignancy From BEVACIZUMAB?
Of the 89 reports, 29 (32.6%) resulted in death, 21 (23.6%) required hospitalization, and 15 (16.9%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BEVACIZUMAB. However, 89 reports have been filed with the FAERS database.
What Other Side Effects Does BEVACIZUMAB Cause?
Off label use (12,094)
Death (8,493)
Diarrhoea (4,911)
Disease progression (4,653)
Fatigue (4,572)
Nausea (4,357)
Hypertension (4,309)
Anaemia (3,221)
Vomiting (3,193)
Neutropenia (2,875)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which BEVACIZUMAB Alternatives Have Lower Second primary malignancy Risk?
BEVACIZUMAB vs BEVACIZUMAB-AWWB
BEVACIZUMAB vs BEVACIZUMAB-BVZR
BEVACIZUMAB vs BEVACIZUMAB-MALY
BEVACIZUMAB vs BEXAROTENE
BEVACIZUMAB vs BEYAZ